American Heart Association (AHA) Scientific Sessions 2022
Chicago, Illinois, US 05 November 2022 - 07 November 2022
Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia
Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.
Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia
23 Dec 2022
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
21 Dec 2022
Do supplements measure up to statins for lipid-lowering?
In individuals with increased 10-year risk for ASCVD*, rosuvastatin 5 mg significantly reduced LDL-C** and other lipid and inflammatory biomarkers compared with placebo and six widely used heart health supplements, results from the SPORT*** trial have shown.
Do supplements measure up to statins for lipid-lowering?
13 Dec 2022
Low-dose polypill: Another step forward in hypertension management?
A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.
Low-dose polypill: Another step forward in hypertension management?
12 Dec 2022
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
04 Dec 2022
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
02 Dec 2022
Chinese herbal med cuts MACCE in STEMI, but questions remain
Tongxinluo, added to guideline-directed therapy, improves outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) in the large, multicentre CTS-AMI* study. But experts are clamouring for more evidence of efficacy.
